TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the Company or PaxMedica) (OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for...
TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a...
TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN “ PaxMedica Inc. (Nasdaq: PXMD) (the Company), a leading biopharmaceutical company dedicated to advancing treatments for...
Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nationsAs previously...
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN “ PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today...
PaxMedica Company Presentation Highlighting Innovations in Autism Disorder
LOS ANGELES, Nov. 17, 2023 (GLOBE NEWSWIRE) -- via IBN “PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announces that...
TARRYTOWN, NY / ACCESSWIRE / November 15, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced today a comprehensive business update along with its financial results for the third quarter ended September 30, 2023.
TARRYTOWN, NY / ACCESSWIRE / November 7, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the publication of research findings in the Annals of General Psychiatry. The research, led by Chief Medical Officer Dr. David Hough, along with a team of renowned co-authors specializing in Autism Spectrum Disorder (ASD), the research explores the potential of low-dose suramin intravenous infusions as an ASD treatment.